© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Expert Interviews
Economic Burden and Quality of Life Impact Associated with Demodex Blepharitis
November 15, 2022
Douglas K. Devries, OD, discusses how Demodex blepharitis affects patients’ quality of life and associated financial burden.
Economic Burden of SMA
November 14, 2022
Julie Parsons, M.D., and John Brandsema, M.D., explore economic burdens associated with SMA.
Disease-Modifying Therapies Across SMA Treatment Landscape
November 10, 2022
Disease-modifying agents play a significant role in treatment strategies for patients with SMA.
Risk Factors for Developing Demodex Blepharitis
November 08, 2022
Douglas K. Devries, OD, outlines the common risk factors associated with Demodex blepharitis.
SMA Prevalence and Disease Burden
November 07, 2022
Julie Parsons, MD, and John Brandsema, MD, open a discussion surrounding prevalence of spinal muscular atrophy (SMA).
Prevalence and Incidence of Demodex Blepharitis
November 01, 2022
Douglas K Devries, OD, illustrates the current prevalence of patients diagnosed with Demodex blepharitis.
Exploring Unmet Needs and Pipeline Treatments for Vitiligo
October 21, 2022
Dr Rosmarin navigates unmet needs and the trajectory of vitiligo treatment.
The 'Niche Solutions' of Value-based Care, per Doug Chaet of Value Evolutions
October 19, 2022
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing and CMS value-based trends vs commercial payer trends. Chaet also addressed the status of select payment models like bundled and episodic, and more.
Doug Chaet of Value Evolutions Sees Value-based Care Programs as Just That: an Evolution
October 18, 2022
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing and CMS value-based trends vs commercial payer trends.
Why Value-based Contracts Are Still the Exception, per Chester "Bernie" Good at UPMC
October 17, 2022
Chester "Bernie" Good, senior medical director for the Center for Value Based Pharmacy Initiatives at UPMC Health Plan, gets in depth on value-based contracts and shares the results of the 2019 contract between UPMC and AstraZeneca for Brilinta. Good addressed value-based contracts last week at AMCP Nexus 2022 conference in National Harbor, Maryland.